Press Release Hub logo
  • Submit a Release
  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

XBiotech Pauses Rheumatology program

Contributed by: GlobeNewswire

Tags

Pharmaceutical

More Like This

Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis

XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis

XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer

XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus

XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus

GlobeNewswire associated0

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

From left to right: Joana Cunha, Head of Corporate Communication and Compliance; Artur Cavaco Paulo, Co-founder, CEO & CSO; Diana Guimarães, Senior Manager of Product Development & Characterization; Eugénia Nogueira, Co-founder, Operations and HR Director

Solfarcos nears completion of Phase 2a clinical trial for methotrexate nanotechnology treatment of Rheumatoid Arthritis

Pages

  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Press Release Hub

  • Our Services
  • Submit a Release

Websites

  • PA Media Group
  • PA Mediapoint
  • Distribution Packages

© PA Media Group. 2026

Terms of Use

Privacy Policy

Contact Us